Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 5:39 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 70 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Cutaneous Lupus Clear all
Completed Phase 2 Interventional Results available

Study to Evaluate BIIB059 (Litifilimab) in Cutaneous Lupus Erythematosus (CLE) With or Without Systemic Lupus Erythematosus (SLE)

NCT02847598
View directory record Official record
Conditions
Systemic Lupus Erythematosus, Active Cutaneous Lupus Erythematosus
Interventions
BIIB059 (litifilimab), Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 75 Years
Enrollment
264 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
53
States / cities
Anniston, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 44 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2023 · Synced Oct 20, 2026, 5:39 PM EDT
Active, not recruiting Phase 2Phase 3 Interventional

A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus

NCT05531565
View directory record Official record
Conditions
Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus
Interventions
Litifilimab, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
62
States / cities
Anniston, Alabama • Birmingham, Alabama • Phoenix, Arizona + 52 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 20, 2026, 5:39 PM EDT
Terminated Phase 2 Interventional Results available

Efficacy and Safety of Delgocitinib Cream in Discoid Lupus Erythematosus.

NCT03958955
View directory record Official record
Conditions
Discoid Lupus Erythematosus
Interventions
Delgocitinib cream, Delgocitinib cream vehicle
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
18 Years to 70 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
5
States / cities
San Diego, California • Skokie, Illinois • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2025 · Synced Oct 20, 2026, 5:39 PM EDT
Terminated Phase 1 Interventional

A Multiple Dose Study Of PD-0360324 In Patients With Active Cutaneous Lupus Erythematosus

NCT01470313
View directory record Official record
Conditions
Cutaneous Lupus Erythematosus
Interventions
PD-0360324, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
21 Years to 70 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
17
States / cities
Anniston, Alabama • Oxford, Alabama • Los Angeles, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2014 · Synced Oct 20, 2026, 5:39 PM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate Safety and Efficacy of Filgotinib and Lanraplenib in Females With Moderately-to-Severely Active Cutaneous Lupus Erythematosus (CLE)

NCT03134222
View directory record Official record
Conditions
Cutaneous Lupus Erythematosus
Interventions
Lanraplenib, Filgotinib, Lanraplenib placebo, Filgotinib placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 75 Years · Female only
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
13
States / cities
Beverly Hills, California • Fullerton, California • Los Angeles, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2020 · Synced Oct 20, 2026, 5:39 PM EDT
Withdrawn Phase 2 Interventional

A Study to Assess the Safety and Efficacy of Secukinumab in Alleviating Symptoms of Discoid Lupus Erythematosus

NCT03866317
View directory record Official record
Conditions
Discoid Lupus Erythematosus
Interventions
Secukinumab
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 8, 2021 · Synced Oct 20, 2026, 5:39 PM EDT
Completed Phase 1 Interventional

Phase Ib Study of SC Milatuzumab in SLE

NCT01845740
View directory record Official record
Conditions
Lupus Erythematosus, Cutaneous, Lupus Erythematosus, Discoid, Lupus Erythematosus, Systemic, Lupus Vasculitis, Central Nervous System, Lupus Nephritis
Interventions
milatuzumab, Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
West Hollywood, California
Source: ClinicalTrials.gov public record
Updated Aug 19, 2021 · Synced Oct 20, 2026, 5:39 PM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers

Vitamin D Status, Disease Specific and Quality of Life Outcomes in Patients With Cutaneous Lupus

NCT01498406
View directory record Official record
Conditions
Cutaneous Lupus Erythematosus
Interventions
vitamin D
Dietary Supplement
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 20, 2013 · Synced Oct 20, 2026, 5:39 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Cutaneous Lupus Registry

NCT01266915
View directory record Official record
Conditions
Lupus Erythematosus
Interventions
Not listed
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2030
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 26, 2025 · Synced Oct 20, 2026, 5:39 PM EDT
Completed Phase 2 Interventional Results available

Dose Finding, Efficacy and Safety of BI 655064 in Patients With Active Lupus Nephritis

NCT02770170
View directory record Official record
Conditions
Lupus Nephritis
Interventions
BI 655064 dose 1, BI 655064 dose 2, BI 655064 dose 3, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 70 Years
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
9
States / cities
Los Angeles, California • Doral, Florida • Kissimmee, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2025 · Synced Oct 20, 2026, 5:39 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Pilot Tape Harvesting Study

NCT02125695
View directory record Official record
Conditions
Atopic Dermatitis, Healthy, Discoid Lupus Erythematosus, Subacute Cutaneous Lupus Erythematosus
Interventions
Skin Taping, Blood Sampling, Skin Biopsy
Procedure
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 28, 2016 · Synced Oct 20, 2026, 5:39 PM EDT
Withdrawn Phase 2 Interventional

Discoid Lupus Erythematosus of the Scalp and a Trial of Biologic Therapy With Raptiva

NCT00308204
View directory record Official record
Conditions
Discoid Lupus Erthematosus of the Scalp
Interventions
Raptiva
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 19, 2020 · Synced Oct 20, 2026, 5:39 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety Study of Clinical and Immune Effects of Phosphodiesterase 4 (PDE-4) Inhibitor in Cutaneous Lupus Patients

NCT00708916
View directory record Official record
Conditions
Discoid Lupus Erythematosus
Interventions
CC-10004
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 65 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 3, 2021 · Synced Oct 20, 2026, 5:39 PM EDT
Not listed Not applicable Interventional

Autologous Peripheral Blood Stem Cell Transplantation in Patients With Life Threatening Autoimmune Diseases

NCT00006055
View directory record Official record
Conditions
Purpura, Schoenlein-Henoch, Graft Versus Host Disease, Anemia, Hemolytic, Autoimmune, Rheumatoid Arthritis, Churg-Strauss Syndrome, Hypersensitivity Vasculitis, Wegener's Granulomatosis, Systemic Lupus Erythematosus, Giant Cell Arteritis, Pure Red Cell Aplasia, Juvenile Rheumatoid Arthritis, Polyarteritis Nodosa, Autoimmune Thrombocytopenic Purpura, Takayasu Arteritis
Interventions
anti-thymocyte globulin, cyclophosphamide, cyclosporine, filgrastim, methylprednisolone, prednisone, Autologous Peripheral Blood Stem Cell Transplantation
Drug · Procedure
Lead sponsor
Fairview University Medical Center
Other
Eligibility
1 Year to 55 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 20, 2026, 5:39 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Maternal Autoimmune Disease Research Alliance (MADRA) Registry

NCT03276923
View directory record Official record
Conditions
Autoimmune Diseases, Pregnancy Related, Systemic Lupus Erythematosus, Cutaneous Lupus, Rheumatoid Arthritis, Sjogren's Syndrome, Scleroderma
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
Female only
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2027
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 8, 2026 · Synced Oct 20, 2026, 5:39 PM EDT
Recruiting Phase 3 Interventional

A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease (ELOWEN-2)

NCT07355218
View directory record Official record
Conditions
Systematic Lupus Erythematosus, Cutaneous Lupus Erythematosus
Interventions
Enpatoran, Placebo, Standard of care (SoC)
Drug
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
14
States / cities
Upland, California • DeBary, Florida • Fort Lauderdale, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 20, 2026, 5:39 PM EDT
Terminated Phase 1 Interventional

Safety Study of AMG 811 in Subjects With Discoid Lupus Erythematosus

NCT01164917
View directory record Official record
Conditions
Cutaneous Lupus, Discoid Lupus, Lupus, Systemic Lupus Erythematosus
Interventions
AMG811, AMG811 Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 70 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
8
States / cities
Santa Monica, California • Stanford, California • Atlanta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2014 · Synced Oct 20, 2026, 5:39 PM EDT
Terminated Phase 2 Interventional

Study of Daxdilimab (HZN-7734) in Participants With Moderate-to-Severe Primary Discoid Lupus Erythematosus

NCT05591222
View directory record Official record
Conditions
Discoid Lupus Erythematosus
Interventions
Placebo, Daxdilimab
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 75 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
16
States / cities
North Little Rock, Arkansas • Beverly Hills, California • Fremont, California + 12 more
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Oct 20, 2026, 5:39 PM EDT
Terminated Phase 2 Interventional Results available

A Study to Learn About the Study Medicine (PF-06823859) in Adults With Active CLE or SLE With Skin Symptoms.

NCT05879718
View directory record Official record
Conditions
Lupus Erythematosus, Systemic, Lupus Erythematosus, Cutaneous
Interventions
Placebo, PF-06823859
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
11
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 20, 2026, 5:39 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Duke Autoimmunity in Pregnancy Registry

NCT00513591
View directory record Official record
Conditions
Pregnancy, Systemic Lupus Erythematosus, Cutaneous Lupus, Rheumatoid Arthritis, Sjogren's Syndrome, Scleroderma
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
18 Years and older · Female only
Enrollment
513 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2018
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 23, 2019 · Synced Oct 20, 2026, 5:39 PM EDT
Recruiting No phase listed Observational

Prevalence and Clinical Severity of Cutaneous Lupus Erythematosus

NCT01510067
View directory record Official record
Conditions
Cutaneous Lupus Erythematosus (CLE)
Interventions
Not listed
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2030
U.S. locations
2
States / cities
Philadelphia, Pennsylvania • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Oct 20, 2026, 5:39 PM EDT
Completed Phase 1 Interventional Results available

Evaluation of Tofacitinib in Prevention of Photosensitivity in Lupus

NCT05048238
View directory record Official record
Conditions
Cutaneous Lupus
Interventions
Tofacitinib
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
2
States / cities
Worcester, Massachusetts • Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 22, 2025 · Synced Oct 20, 2026, 5:39 PM EDT
Active, not recruiting Phase 2 Interventional

The Willow LTE Study With M5049 in Participants With SCLE, DLE and/or SLE (WILLOW LTE)

NCT05540327
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
M5049 low dose, M5049 medium dose, M5049 high dose, Placebo
Drug
Lead sponsor
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Industry
Eligibility
18 Years to 76 Years
Enrollment
381 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
8
States / cities
Torrance, California • Brandon, Florida • Miami, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 20, 2026, 5:39 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Microvascular and Fibrosis Imaging Study

NCT01758250
View directory record Official record
Conditions
Autoimmune Diseases, Sickle Cell Disease, Chronic Graft Versus Host Disease
Interventions
Acoustic Radiation Force Impulse (ARFI), Laser Doppler Flowmetry (LDF), Laser Doppler Perfusion Imaging (LDI), Optical Coherence Tomography (OCT), Orthogonal Polarization Spectral Imaging (OPSI), Nail fold video capillaroscopy (NVC)
Other
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2018
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 11, 2020 · Synced Oct 20, 2026, 5:39 PM EDT